Epigenetic age and long-term cancer risk following a stroke
Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development...
Saved in:
| Published in | Genome medicine Vol. 16; no. 1; pp. 135 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
22.11.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1756-994X 1756-994X |
| DOI | 10.1186/s13073-024-01408-2 |
Cover
| Abstract | Background
The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE.
Methods
From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, Zhang
BLUP
, Zhang
EN
, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables.
Results
Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum’s EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02–1.10],
p
value = 0.002).
Conclusions
Our findings suggest that epigenetic accelerated aging, as indicated by Hannum’s EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. |
|---|---|
| AbstractList | BackgroundThe association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE.MethodsFrom our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, ZhangBLUP, ZhangEN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables.ResultsAmong 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum’s EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02–1.10], p value = 0.002).ConclusionsOur findings suggest that epigenetic accelerated aging, as indicated by Hannum’s EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE. Methods From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, Zhang BLUP , Zhang EN , and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables. Results Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum’s EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02–1.10], p value = 0.002). Conclusions Our findings suggest that epigenetic accelerated aging, as indicated by Hannum’s EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE.BACKGROUNDThe association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE.From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, ZhangBLUP, ZhangEN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables.METHODSFrom our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, ZhangBLUP, ZhangEN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables.Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum's EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02-1.10], p value = 0.002).RESULTSAmong 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum's EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02-1.10], p value = 0.002).Our findings suggest that epigenetic accelerated aging, as indicated by Hannum's EEAA, may play a significant role in the increased cancer risk observed in CVE survivors.CONCLUSIONSOur findings suggest that epigenetic accelerated aging, as indicated by Hannum's EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. Abstract Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE. Methods From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, ZhangBLUP, ZhangEN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables. Results Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum’s EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02–1.10], p value = 0.002). Conclusions Our findings suggest that epigenetic accelerated aging, as indicated by Hannum’s EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE. From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, Zhang.sub.BLUP, Zhang.sub.EN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables. Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum's EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02-1.10], p value = 0.002). Our findings suggest that epigenetic accelerated aging, as indicated by Hannum's EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE. Methods From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, Zhang.sub.BLUP, Zhang.sub.EN, and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables. Results Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum's EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02-1.10], p value = 0.002). Conclusions Our findings suggest that epigenetic accelerated aging, as indicated by Hannum's EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. Keywords: DNA methylation, Epigenetic clock, Aging, Stroke, Cancer The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age) acceleration is involved in this association. Our study aims to examine B-age as a novel contributing factor to cancer development post-CVE. From our prospective stroke registry (BasicMar), we selected 940 cases with epigenetic data. For this study, we specifically analyzed 648 of these patients who had available data, no prior history of cancer, and a minimum follow-up of 3 months. The primary outcome was cancer incidence. B-age was estimated using DNA methylation data derived from whole blood samples obtained within 24 h of stroke onset, employing various epigenetic clocks (including Hannum, Horvath, PhenoAge, Zhang , Zhang , and the mitotic epiTOC). Extrinsic epigenetic age acceleration (EEAA) was calculated as the residuals from the regression of B-age against chronological age (C-age). For epiTOC, the age-adjusted values were obtained by regressing out the effect of age from the raw epiTOC measurements. Estimated white cell counts were derived from DNA methylation data, and these cell fractions were used to compute the intrinsic epigenetic age acceleration (IEAA). Subsequently, we evaluated the independent association between EEAA, IEAA, and cancer incidence while controlling for potential confounding variables. Among 648 patients with a median follow-up of 8.15 years, 83 (12.8%) developed cancer. Cox multivariable analyses indicated significant associations between Hannum, Zhang, and epiTOC EEAA and the risk of cancer after CVE. After adjusting for multiple testing and competing risks, EEAA measured by Hannum clock maintained an independent association with cancer risk. Specifically, for each year increase in Hannum's EEAA, we observed a 6.0% increased incidence of cancer (HR 1.06 [1.02-1.10], p value = 0.002). Our findings suggest that epigenetic accelerated aging, as indicated by Hannum's EEAA, may play a significant role in the increased cancer risk observed in CVE survivors. |
| ArticleNumber | 135 |
| Audience | Academic |
| Author | Giralt-Steinhauer, Eva Campanale, Maia Rodríguez-Campello, Ana Ois, Angel Fernández-Pérez, Isabel Guisado-Alonso, Daniel Suárez-Pérez, Antoni Jiménez-Balado, Joan Jiménez-Conde, Jordi Macias-Gómez, Adrià Cuadrado-Godia, Elisa Vallverdú-Prats, Marta |
| Author_xml | – sequence: 1 givenname: Antoni surname: Suárez-Pérez fullname: Suárez-Pérez, Antoni organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Medicine Department, Universitat Autònoma de Barcelona – sequence: 2 givenname: Adrià surname: Macias-Gómez fullname: Macias-Gómez, Adrià organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Medicine Department, Universitat Autònoma de Barcelona – sequence: 3 givenname: Isabel surname: Fernández-Pérez fullname: Fernández-Pérez, Isabel organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Medicine Department, Universitat Autònoma de Barcelona – sequence: 4 givenname: Marta surname: Vallverdú-Prats fullname: Vallverdú-Prats, Marta organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute – sequence: 5 givenname: Elisa surname: Cuadrado-Godia fullname: Cuadrado-Godia, Elisa organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Universitat Pompeu Fabra – sequence: 6 givenname: Eva surname: Giralt-Steinhauer fullname: Giralt-Steinhauer, Eva organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Universitat Pompeu Fabra – sequence: 7 givenname: Maia surname: Campanale fullname: Campanale, Maia organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute – sequence: 8 givenname: Daniel surname: Guisado-Alonso fullname: Guisado-Alonso, Daniel organization: Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra – sequence: 9 givenname: Ana surname: Rodríguez-Campello fullname: Rodríguez-Campello, Ana organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Universitat Pompeu Fabra – sequence: 10 givenname: Joan orcidid: 0000-0003-4125-9134 surname: Jiménez-Balado fullname: Jiménez-Balado, Joan email: jjimenez3@researchmar.net organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute – sequence: 11 givenname: Jordi surname: Jiménez-Conde fullname: Jiménez-Conde, Jordi organization: Neurovascular Research Group, Hospital del Mar Medical Research Institute, Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Universitat Pompeu Fabra – sequence: 12 givenname: Angel surname: Ois fullname: Ois, Angel organization: Department of Neurology, Hospital Del Mar and Universitat Pompeu Fabra, Universitat Pompeu Fabra |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39578904$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1r1jAUx4tM3It-AS-kIIg3nXltE7waY-pg4I2Cd-E0Pe3yrE0ek5bhtzfdM_eGjFwknPz-5_2w2PPBY1G8peSYUlV_SpSThleEiYpQQVTFXhQHtJF1pbX4tffgvV8cprQhpBZMNK-Kfa5lozQRB8Xns60b0OPsbAkDluC7cgx-qGaMU2nBW4xldOmq7MM4hmvnhxLKNMdwha-Llz2MCd_c3kfFzy9nP06_VRffv56fnlxUVio-Vy0BQaRSSFlDQBLO-r4lFur1VYPGrlGSaq0ayVStZd9rIilkK6NScMuPivOd3y7AxmyjmyD-MQGcuTGEOBiIuYARTYNAOklV23RcaMvbmjJGakDoW2CEZV8fd762MfxeMM1mcsniOILHsCTDKWdUcEZERt8_QTdhiT5XavI_rQnhQt5TA-T4zvdhjmBXp-ZE0YZTphXN1PF_qHw6nJzNY-1dtj8SfHgguEQY58sUxmV2wafH4LvbLJd2wu6uPf9GnAG2A2wMKUXs7xBKzLpHZrdHJu-Rudkjs7ZJPRFZN8MaPOftxuelfCdNOY4fMN637RnVX0WY1cQ |
| CitedBy_id | crossref_primary_10_1186_s13073_024_01408_2 |
| Cites_doi | 10.18632/aging.101414 10.1016/j.canep.2020.101802 10.1007/s00432-019-03022-x 10.1155/2020/1047896 10.1186/s13059-016-1064-3 10.1093/nar/gks1193 10.1161/STROKEAHA.121.037419 10.1016/S0140-6736(16)31012-1 10.1186/s13072-019-0321-6 10.1155/2021/5585206 10.1101/2022.02.13.480245 10.1111/ene.14037 10.1186/s13148-024-01690-2 10.1159/000440730 10.3390/ijms232415769 10.1159/000375154 10.1007/s00432-019-02855-w 10.1186/s13073-024-01408-2 10.1007/s11060-017-2741-0 10.1038/s41467-021-27864-7 10.1212/WNL.0000000000004261 10.1186/gb-2013-14-10-r115 10.1111/ane.13192 10.18632/aging.101028 10.1158/1055-9965.EPI-08-1118 10.1111/j.2517-6161.1995.tb02031.x 10.1016/j.arr.2021.101314 10.1161/01.STR.24.1.35 10.1177/23969873231181628 10.1007/s12975-024-01252-x 10.1093/bioinformatics/btu049 10.1093/bioinformatics/bts680 10.18632/aging.101684 10.1007/s11357-023-01029-4 10.1136/jnnp-2023-332889 10.1016/j.jaccao.2020.12.003 10.1002/ajhb.23488 10.1161/HYPERTENSIONAHA.111.189258 10.1158/1055-9965.EPI-13-0444 10.1161/JAHA.118.009543 10.1161/STROKEAHA.115.008694 10.1017/cjn.2021.55 10.1001/jamanetworkopen.2023.5002 10.1016/j.molcel.2012.10.016 10.1186/s13148-019-0656-7 10.3390/ijms24032759 10.1016/j.ebiom.2016.02.008 10.1161/01.STR.19.5.604 10.1186/s13073-019-0667-1 10.1186/s13073-023-01211-5 10.1038/s41592-018-0213-x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 DOA |
| DOI | 10.1186/s13073-024-01408-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1756-994X |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_7ea0d518b7d349c3b612206aeafba202 A817312981 39578904 10_1186_s13073_024_01408_2 |
| Genre | Journal Article |
| GeographicLocations | Netherlands |
| GeographicLocations_xml | – name: Netherlands |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACJQM ACUHS ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIAM BBNVY BENPR BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 LK8 M1P M7P MK0 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ TUS UKHRP AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c583t-b0a40588e1270a5032ffb0ca6032f6a9ed78519987528695ff9051ad7821543c3 |
| IEDL.DBID | 7X7 |
| ISSN | 1756-994X |
| IngestDate | Wed Aug 27 01:29:03 EDT 2025 Fri Sep 05 10:28:02 EDT 2025 Fri Jul 25 19:31:18 EDT 2025 Tue Jun 17 21:56:36 EDT 2025 Tue Jun 10 20:54:15 EDT 2025 Thu May 22 21:23:28 EDT 2025 Mon Jul 21 05:55:21 EDT 2025 Tue Jul 01 04:01:14 EDT 2025 Thu Apr 24 22:57:23 EDT 2025 Sat Sep 06 07:28:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | DNA methylation Aging Stroke Epigenetic clock Cancer |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-b0a40588e1270a5032ffb0ca6032f6a9ed78519987528695ff9051ad7821543c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-4125-9134 |
| OpenAccessLink | https://www.proquest.com/docview/3201600345?pq-origsite=%requestingapplication% |
| PMID | 39578904 |
| PQID | 3201600345 |
| PQPubID | 2040231 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7ea0d518b7d349c3b612206aeafba202 proquest_miscellaneous_3132143204 proquest_journals_3201600345 gale_infotracmisc_A817312981 gale_infotracacademiconefile_A817312981 gale_healthsolutions_A817312981 pubmed_primary_39578904 crossref_primary_10_1186_s13073_024_01408_2 crossref_citationtrail_10_1186_s13073_024_01408_2 springer_journals_10_1186_s13073_024_01408_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-11-22 |
| PublicationDateYYYYMMDD | 2024-11-22 |
| PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Genome medicine |
| PublicationTitleAbbrev | Genome Med |
| PublicationTitleAlternate | Genome Med |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | Q Luo (1408_CR31) 2023; 15 JC Van Swieten (1408_CR18) 1988; 19 T Stocks (1408_CR34) 2012; 59 J Jiménez-Balado (1408_CR15) 2023; 12 Y Zheng (1408_CR12) 2016; 5 C Tanislav (1408_CR37) 2019; 145 PD Fransquet (1408_CR11) 2019; 11 HA Selvik (1408_CR39) 2015; 5 A Macias-Gómez (1408_CR16) 2024; 95 MY Sun (1408_CR2) 2022; 23 AI Qureshi (1408_CR50) 2015; 39 MJ Aryee (1408_CR20) 2014; 30 S Horvath (1408_CR26) 2013; 14 AT Lu (1408_CR44) 2019; 11 ME Levine (1408_CR27) 2018; 10 1408_CR21 Z Yang (1408_CR29) 2016; 17 CP Ryan (1408_CR10) 2021; 33 CG Vaz (1408_CR41) 2023; 8 T Barrett (1408_CR52) 2013; 41 AJ Tybjerg (1408_CR5) 2020; 141 ES Lau (1408_CR35) 2021; 3 BA Labarre (1408_CR23) 2019; 12 S Quintas (1408_CR40) 2018; 137 R Noroozi (1408_CR47) 2024; 46 J Wilbers (1408_CR6) 2020; 27 J Jiménez-Balado (1408_CR22) 2024; 16 1408_CR19 AE Teschendorff (1408_CR24) 2013; 29 C Soriano-Tárraga (1408_CR14) 2017; 89 R Erichsen (1408_CR51) 2013; 22 1408_CR55 1408_CR54 1408_CR53 G Hannum (1408_CR25) 2013; 49 N Vinter (1408_CR36) 2018; 7 SC Zheng (1408_CR32) 2018; 15 NG Zaorsky (1408_CR3) 2019; 10 LA Salas (1408_CR30) 2022; 13 J Jiang (1408_CR4) 2021; 2021 B Rioux (1408_CR7) 2022; 49 Q Zhang (1408_CR28) 2019; 11 S Jiang (1408_CR9) 2020; 2020 JI Verhoeven (1408_CR42) 2023; 6 Y Benjamini (1408_CR33) 1995; 57 1408_CR46 C Gallego-Fabrega (1408_CR45) 2022; 53 L Jacob (1408_CR8) 2019; 145 MB Cook (1408_CR49) 2009; 18 R Noroozi (1408_CR48) 2021; 68 H Wang (1408_CR1) 2016; 388 A Miranda-Filho (1408_CR43) 2020; 69 I Fernández-Pérez (1408_CR17) 2023; 24 C Soriano-Tárraga (1408_CR13) 2016; 8 K Aarnio (1408_CR38) 2015; 46 |
| References_xml | – volume: 10 start-page: 573 year: 2018 ident: 1408_CR27 publication-title: Aging doi: 10.18632/aging.101414 – volume: 69 year: 2020 ident: 1408_CR43 publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2020.101802 – volume: 145 start-page: 3047 year: 2019 ident: 1408_CR37 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-019-03022-x – volume: 2020 start-page: 1047896 year: 2020 ident: 1408_CR9 publication-title: Stem Cells Int. doi: 10.1155/2020/1047896 – volume: 17 start-page: 1 year: 2016 ident: 1408_CR29 publication-title: Genome Biol. doi: 10.1186/s13059-016-1064-3 – volume: 41 start-page: D991 year: 2013 ident: 1408_CR52 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gks1193 – ident: 1408_CR55 – volume: 53 start-page: 2320 year: 2022 ident: 1408_CR45 publication-title: Stroke doi: 10.1161/STROKEAHA.121.037419 – volume: 388 start-page: 1459 year: 2016 ident: 1408_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(16)31012-1 – volume: 12 start-page: 79 year: 2019 ident: 1408_CR23 publication-title: Epigenetics Chromatin. doi: 10.1186/s13072-019-0321-6 – volume: 2021 start-page: 5585206 year: 2021 ident: 1408_CR4 publication-title: Biomed Res Int. doi: 10.1155/2021/5585206 – ident: 1408_CR46 doi: 10.1101/2022.02.13.480245 – volume: 27 start-page: 85 year: 2020 ident: 1408_CR6 publication-title: Eur J Neurol doi: 10.1111/ene.14037 – volume: 16 start-page: 75 year: 2024 ident: 1408_CR22 publication-title: Clin Epigenetics. doi: 10.1186/s13148-024-01690-2 – volume: 5 start-page: 107 year: 2015 ident: 1408_CR39 publication-title: Cerebrovasc Dis Extra doi: 10.1159/000440730 – volume: 23 start-page: 15769 year: 2022 ident: 1408_CR2 publication-title: Int J Mol Sci. doi: 10.3390/ijms232415769 – volume: 39 start-page: 262 year: 2015 ident: 1408_CR50 publication-title: Cerebrovasc Dis doi: 10.1159/000375154 – volume: 145 start-page: 1013 year: 2019 ident: 1408_CR8 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-019-02855-w – ident: 1408_CR53 doi: 10.1186/s13073-024-01408-2 – volume: 137 start-page: 551 year: 2018 ident: 1408_CR40 publication-title: J Neurooncol doi: 10.1007/s11060-017-2741-0 – volume: 13 start-page: 761 year: 2022 ident: 1408_CR30 publication-title: Nat Commun. doi: 10.1038/s41467-021-27864-7 – volume: 89 start-page: 830 year: 2017 ident: 1408_CR14 publication-title: Neurology doi: 10.1212/WNL.0000000000004261 – volume: 14 start-page: R115 year: 2013 ident: 1408_CR26 publication-title: Genome Biol. doi: 10.1186/gb-2013-14-10-r115 – volume: 141 start-page: 204 year: 2020 ident: 1408_CR5 publication-title: Acta Neurol Scand doi: 10.1111/ane.13192 – volume: 8 start-page: 2655 year: 2016 ident: 1408_CR13 publication-title: Aging (Albany NY) doi: 10.18632/aging.101028 – volume: 12 start-page: 33 year: 2023 ident: 1408_CR15 publication-title: Biology (Basel) – volume: 18 start-page: 1174 year: 2009 ident: 1408_CR49 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-08-1118 – volume: 57 start-page: 289 year: 1995 ident: 1408_CR33 publication-title: J Roy Stat Soc: Ser B (Methodol) doi: 10.1111/j.2517-6161.1995.tb02031.x – volume: 68 year: 2021 ident: 1408_CR48 publication-title: Ageing Res Rev doi: 10.1016/j.arr.2021.101314 – ident: 1408_CR19 doi: 10.1161/01.STR.24.1.35 – volume: 8 start-page: 792 year: 2023 ident: 1408_CR41 publication-title: Eur Stroke J doi: 10.1177/23969873231181628 – ident: 1408_CR54 doi: 10.1186/s13073-024-01408-2 – ident: 1408_CR21 doi: 10.1007/s12975-024-01252-x – volume: 30 start-page: 1363 year: 2014 ident: 1408_CR20 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu049 – volume: 29 start-page: 189 year: 2013 ident: 1408_CR24 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts680 – volume: 11 start-page: 303 year: 2019 ident: 1408_CR44 publication-title: Aging doi: 10.18632/aging.101684 – volume: 46 start-page: 2583 year: 2024 ident: 1408_CR47 publication-title: Geroscience doi: 10.1007/s11357-023-01029-4 – volume: 95 start-page: 675 year: 2024 ident: 1408_CR16 publication-title: J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2023-332889 – volume: 3 start-page: 48 year: 2021 ident: 1408_CR35 publication-title: JACC CardioOncol doi: 10.1016/j.jaccao.2020.12.003 – volume: 33 start-page: 1 year: 2021 ident: 1408_CR10 publication-title: Am J Hum Biol doi: 10.1002/ajhb.23488 – volume: 59 start-page: 802 year: 2012 ident: 1408_CR34 publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.111.189258 – volume: 22 start-page: 1994 year: 2013 ident: 1408_CR51 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-13-0444 – volume: 7 start-page: e009543 year: 2018 ident: 1408_CR36 publication-title: J Am Heart Assoc. doi: 10.1161/JAHA.118.009543 – volume: 46 start-page: 1601 year: 2015 ident: 1408_CR38 publication-title: Stroke doi: 10.1161/STROKEAHA.115.008694 – volume: 49 start-page: 225 year: 2022 ident: 1408_CR7 publication-title: Can J Neurol Sci doi: 10.1017/cjn.2021.55 – volume: 6 start-page: e235002 year: 2023 ident: 1408_CR42 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2023.5002 – volume: 49 start-page: 359 year: 2013 ident: 1408_CR25 publication-title: Mol Cell doi: 10.1016/j.molcel.2012.10.016 – volume: 11 start-page: 62 year: 2019 ident: 1408_CR11 publication-title: Clin Epigenetics. doi: 10.1186/s13148-019-0656-7 – volume: 24 start-page: 2759 year: 2023 ident: 1408_CR17 publication-title: Int J Mol Sci. doi: 10.3390/ijms24032759 – volume: 5 start-page: 68 year: 2016 ident: 1408_CR12 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.02.008 – volume: 19 start-page: 604 year: 1988 ident: 1408_CR18 publication-title: Stroke doi: 10.1161/01.STR.19.5.604 – volume: 10 start-page: 5172 year: 2019 ident: 1408_CR3 publication-title: Stroke among cancer patients. Nat Commun. – volume: 11 start-page: 54 year: 2019 ident: 1408_CR28 publication-title: Genome Med. doi: 10.1186/s13073-019-0667-1 – volume: 15 start-page: 59 year: 2023 ident: 1408_CR31 publication-title: Genome Med. doi: 10.1186/s13073-023-01211-5 – volume: 15 start-page: 1059 year: 2018 ident: 1408_CR32 publication-title: Nat Methods doi: 10.1038/s41592-018-0213-x |
| SSID | ssj0064247 |
| Score | 2.4023652 |
| Snippet | Background
The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological... The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological age (B-age)... Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological... BackgroundThe association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that biological... Abstract Background The association between increased cancer risk following a cerebrovascular event (CVE) has been previously reported. We hypothesize that... |
| SourceID | doaj proquest gale pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 135 |
| SubjectTerms | Advances in healthy aging and age-related diseases Age Age Factors Aged Aged, 80 and over Aging Aging - genetics B cells Bioinformatics Biomedical and Life Sciences Biomedicine Blood cell count Cancer Cancer Research Development and progression DNA Methylation Epigenesis, Genetic Epigenetic clock Epigenetic inheritance Epigenetics Ethylenediaminetetraacetic acid Female Hospitals Human Genetics Humans Incidence Ischemia Male Medical diagnosis Medical records Medicine/Public Health Metabolomics Methylation Middle Aged Mortality Neoplasms - complications Neoplasms - genetics Oncology, Experimental Patients Primary care Prospective Studies Risk Factors Stroke Stroke - epidemiology Stroke - etiology Stroke - genetics Systems Biology Tumors Variables |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiPJMW8BISBzAavyMrZ4KalUhwYlKvVm243CgSqrdrRD_npk4Cd0i4MItG4-TzecZz4xsf0PI6-iw5HsXWds6w1RjFHNWwM9GC8tzCx4GV3Q_fTZn5-rjhb64UeoL94QVeuAC3GGTQ91qbmPTSuWSjOCSRW1CDl0MotBI1q6ek6kyB0NQrZr5iIw1h2uOqszAHzHMKEA3ttzQyNb_-5x8wyndWiUdnc_pA3J_ihrpcfm3u-RO7h-Su6WO5I9H5OjkCkk18TwihfmBhr6ll0P_leG8SxMO7IriJnLawbAP3-EdNND1ZjV8y4_J-enJlw9nbKqKwJK2csNiHSDIsjbjmnHQtRRdF-sUDF6Z4HIL4OPJOUTbON11SMEV4C54dyWTfEJ2-qHPzwh1NkRtIyQJDaTJyTotdODBGKtcNEJUhM8g-TRRhmPliks_pg7W-AKsB2D9CKyHPm-XPleFMOOv0u8R-0USya7HG6ACflIB_y8VqMhLHDlfTo4uJuuPLW8kxDOWV-TNKIFGCx-QwnT2AGBA-qstyYMtSTC2tN08a4efjH3tpUCavloqXZFXSzP2xA1sfR6uQYZjRSiQVBV5WrRq-WhcKrUOW97Navbr4X_Gbu9_YLdP7gk0C86ZEAdkZ7O6zs8hzNrEF6NF_QROaBqt priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NaxUxEA-1IngRtdW-tmoKQg8a3HxuQk_to6UU9GSht5Bksx4su-W9V8T_3pn9sk-r0NtuMtllfzOTmTA7M4S8jw5bvteRVZUzTJVGMWcF3JZaWJ4rsDAY0f38xZxfqosrfTWUycFcmLvxe27NpyVHIWRgSRieBYCrj8hjDYMozXMzH3ddcKNVOSbF3LtuzfB09fn_3oXvmKE_4qKduTl7Tp4NfiI97hn7gmzk5iV50neO_LlFjk5vsIwmZiBS2BFoaCp63TbfGO60NCErFxR_G6c1MLr9Ae-ggS5Xi_Z73iaXZ6df5-ds6IPAkrZyxWIRwK2yNmOUOOhCirqORQoGr0xwuQK4MVcO8TVO1zUW3QowCvZcySRfkc2mbfIOoc6GqG2EY0EJB-NknRY68GCMVS4aIWaEjyD5NBQJx14V1747LFjje2A9AOs7YD2s-TCtuelLZPyX-gSxnyixvHU3AFz3g7b4Moei0tzGspLKJRnBDxOFCTnUMYgCHvIOOef7XNFJSf2x5aUED8byGTnsKFBN4QNSGLINAAYseLVGub9GCeqV1qdH6fCDei-9FFiYr5BKz8jBNI0r8Ze1Jre3QMOxBxRQqhl53UvV9NEYHLUOZz6OYvb74f_Gbvdh5HvkqUAF4JwJsU82V4vb_AZcqFV82-nOL-K-Cqo priority: 102 providerName: Springer Nature |
| Title | Epigenetic age and long-term cancer risk following a stroke |
| URI | https://link.springer.com/article/10.1186/s13073-024-01408-2 https://www.ncbi.nlm.nih.gov/pubmed/39578904 https://www.proquest.com/docview/3201600345 https://www.proquest.com/docview/3132143204 https://doaj.org/article/7ea0d518b7d349c3b612206aeafba202 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0IJNSLwgvimMYiQkHsBa7MSOLR7QVnVMSEwIMalvlu04e9iUlLbTtH_PnfMxCmIvVROf0-Z8nz7fHSHvvMGW77VnVWUUK0pVMKMFXJZSaB4r0DAY0f12oo5Pi68Lueg33Nb9scpBJiZBXbUB98j3c4G10LK8kJ-Xvxh2jcLoat9C4y7Z5WCJYOuGcjE6XGBaF-WQKKPV_pojQTPQSgz9CqCQLWWUavb_K5n_UE1_xUqTCjp6SB70tiM96Bb7EbkTm8fkXtdN8voJ-TRfYmlNzEqkICWoayp60TZnDKUvDbi8K4pHyWkNi99ewW9QR9ebVXsen5LTo_nP2THreyOwIHW-YT5zYGppHTFy7GSWi7r2WXAKvylnYgVLgPlziHNlZF1jIS4Hd0HHF3nIn5Gdpm3iC0KNdl5qD65CCc5y0EYK6bhTShfGKyEmhA9IsqEvHI79Ky5sciC0sh1iLSDWJsRamPNhnLPsymbcCn2IuB8hseR1utGuzmzPQbaMLqsk176s8sKE3INtJjLloqu9Exk85A2unO3yR0fGtQealzlYNZpPyPsEgawLLxBcn4EAaMAiWFuQe1uQwHJhe3igDtuz_NreEOiEvB2HcSYeY2tiewkwHPtCAWQxIc87qhpfGgOm2uDIx4HMbh7-f9y9vP2_vCL3BRI850yIPbKzWV3G12BGbfw08cqU7B7OT77_gKuZmk3TlgR8flnw30vEFho |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CpbIbgg3iwUaiQQB7CaOI5jC1Woha22tF0h1Eq9ubbj9ECVLLtbVf05vo2ZvMqC6K23JB47yWSeGc8MIW-cxpbvhWN5riUTmRRMKw6nWcpVHHLQMBjRPZjI8ZH4epwer5BfXS4MbqvsZGItqPPK4z_yjYRjLbQoEemn6U-GXaMwutq10LBta4V8sy4x1iZ27IXLC3Dh5pu7X-B7v-V8Z3T4eczaLgPMpypZMBdZMFqUChiDtWmU8KJwkbcSj6TVIcf-9eCV4NNLnRYFlrSycBW0pUh8AuveIqsCf6AMyOr2aPLte6cLwLgXWZeqo-TGPEaWYqAXGXo2QKNL6rDuGvCvbvhDOf4Vra2V4M59cq-1XulWQ24PyEooH5LbTT_Ly0fk42iKxT0xL5KCnKK2zOlZVZ4ylP_UI4HNKG5mpwWQX3UB96CWzhez6kd4TI5uBG9PyKCsyvCMUK2sS5UDZyUDd90rnfLUxlZKJbSTnA9J3CHJ-LZ0OXbQODO1C6OkaRBrALGmRqyBOe_7OdOmcMe10NuI-x4Si27XF6rZqWl52GTBRjlQl8vyRGifOLAOeSRtsIWzPIJF1vHLmSaDtRcdZkvFWQJ2lYqH5F0NgcIDXsDbNgcC0IBluJYg15Yggen98nBHHaYVOnNzxSJD8rofxpm4ka4M1TnAxNiZCiDFkDxtqKp_aQzZKo0jHzoyu1r8_7h7fv2zrJM748ODfbO_O9l7Qe5yJP44ZpyvkcFidh5eglG3cK9azqHk5KaZ9TcLHFLV |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagCNQL4lkWCjUSEgewGju2Y4tTWboqr4oDlXqzbMfpgSpZ7aaq-PfM5EWXl8QticeOPOPxjDWebwh5ESyWfK8CK0urmSy0ZNYIeC2UMDyVYGEwovv5WB-dyA-n6vRKFn93230MSfY5DYjSVLf7y7LqVdzo_TXHpcnAvjA8IYCsr5MbiNWFl_rmej7uxeBcy2JMlfljvw1z1KH2_743XzFOv0RLOyO0uENuD94jPejFfZdcS_U9crOvJ_n9PnlzuERwTcxLpLBPUF-X9LypzxjuvzSigFcUL5PTCsTfXMI_qKfrdtV8Sw_IyeLw6_yIDdURWFQmb1nIPDhbxiSMHXuV5aKqQha9xiftbSpBCJhBh1zXVlUVQnF5-ApWXuYxf0i26qZOjwi1xgdlAhwWCjguR2OVUJ57rY20QQsxI3xkkosDdDhWsDh33RHCaNcz1gFjXcdYB31eTX2WPXDGP6nfIu8nSgS97j40qzM36JArks9KxU0oylzamAfwzkSmffJV8CKDQfZQcq7PIJ1U1x0YXuTg1xg-Iy87ClRemED0Qw4CsAFhsDYodzcoQeniZvO4Otyg9GuXC4Try3KpZuT51Iw98SJbnZoLoOFYGQoo5Yzs9KtqmjSGTI3FltfjMvs5-N959_j_yPfIrS_vFu7T--OPT8i2QF3gnAmxS7ba1UV6Cj5WG551avQDQCEV6Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epigenetic+age+and+long-term+cancer+risk+following+a+stroke&rft.jtitle=Genome+medicine&rft.au=Su%C3%A1rez-P%C3%A9rez%2C+Antoni&rft.au=Macias-G%C3%B3mez%2C+Adri%C3%A0&rft.au=Fern%C3%A1ndez-P%C3%A9rez%2C+Isabel&rft.au=Vallverd%C3%BA-Prats%2C+Marta&rft.date=2024-11-22&rft.pub=BioMed+Central+Ltd&rft.issn=1756-994X&rft.eissn=1756-994X&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs13073-024-01408-2&rft.externalDocID=A817312981 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-994X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-994X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-994X&client=summon |